Design a Direct RNA Sequencing Pilot with CD Genomics: KPIs

At a glance:

• Key takeaways
• If You Can’t Measure Success, You Can’t Approve the Pilot (Attention)
• The Pilot’s Single Decision Output: What Will This Pilot Let You Decide? (Advantage)
• KPI Architecture: Three Layers You Must Lock Before Samples Ship (Advantage)
• Input QC Gate KPIs: The Fastest Way to Prevent Reruns (Authority)
• Run Performance KPIs: What “Good Data” Looks Like Beyond Raw Output (Authority)
• Endpoint Evidence KPIs: Isoforms, Modifications, and “Decision‑Grade” Confidence (Authority)
• Rerun and Stop Rules: The KPI That Protects Your Timeline (Authority)
• The Minimal SOW Template: What to Specify So Nothing Becomes “Assumed” (Advantage → Action)
• FAQ: Direct RNA Sequencing Pilot Design and KPIs (AI GEO Optimization)
• Action: Start Your Pilot Design Review (KPIs → SOW → Kickoff) (Action)

CD Genomics Long‑Read Sequencing Team — Pilot Operations & Governance. Hands‑on experience with Oxford Nanopore Direct RNA workflows, Dorado/Remora analysis, and audit‑ready KPI reporting for regulated R&D. Provides practical, SOW‑ready pilot templates and governance-focused guidance.

If you want a Direct RNA Sequencing pilot design that can actually be approved, define success in SOW‑grade terms from day one. Direct RNA Sequencing pilot design isn’t a mini production run—it’s a decision instrument. The fastest way to win budget and set a defensible go/no‑go is to lock DRS pilot KPIs that tie input QC gates, run performance, and endpoint evidence into a single stack. Put plainly: Direct RNA Sequencing pilot design must specify measurable acceptance criteria, transparent rerun triggers, and audit‑ready deliverables.

Key takeaways

• Define one primary decision output—endpoint feasibility—and make success measurable in SOW language.
• Lock a three‑layer KPI stack before samples ship: Input QC Gates → Run Performance → Endpoint Evidence.
• Use isoform resolution as the acceptance gate (Medium tier minimum), and treat modification feasibility as Exploratory.
• Convert reruns into policy: one troubleshooting cycle per batch, evidence‑tied triggers, and stop/rescope if the gate isn’t met.
• Deliver audit‑ready artifacts: per‑sample QC, KPI dashboard, evidence tiers, and a brief pipeline version‑lock statement.

If You Can’t Measure Success, You Can’t Approve the Pilot (Attention)

Most pilots fail for a simple reason: “success” was never defined in measurable terms. In regulated R&D, vague objectives create scope creep, budget friction, and indecisive reviews. Write success the way procurement and legal expect to read it: acceptance criteria, KPI thresholds, evidence tiers, and policy‑level rerun/stop rules. When these elements are explicit, you can defend buffers, make trade‑offs visible, and issue a clean go/no‑go.

The Pilot’s Single Decision Output: What Will This Pilot Let You Decide? (Advantage)

Treat the pilot as a decision instrument, not a scaled‑down production run. Choose exactly one primary decision:

• Route selection (DRS vs cDNA long‑read vs hybrid)
• Endpoint feasibility (isoforms, modifications) — recommended as the primary decision
• Evidence defensibility (internal review success probability)
• Operational feasibility (TAT, cost, batch consistency)

For most pharma teams, endpoint feasibility—specifically isoform resolution—makes the cleanest acceptance gate: “Pilot is successful if endpoint evidence reaches at least Medium tier under pre‑defined QC gates.” If you need general context on DRS capabilities and typical inputs, see the Direct RNA Sequencing overview on CD Genomics’ site in the background sense via the company’s DRS page: Direct RNA Sequencing service overview.

KPI Architecture: Three Layers You Must Lock Before Samples Ship (Advantage)

A simple, auditable KPI architecture prevents scope creep:

• Input QC Gate KPIs (acceptance criteria)
• Run Performance KPIs (usable data, consistency)
• Endpoint Evidence KPIs (tiered decision‑grade outputs)

This stack aligns lab operations, bioinformatics, and governance. It also mirrors how ONT’s workflow and monitoring tooling help you track what matters—inputs, run health, and downstream evidence—without relying on a single metric. For chemistry and workflow context, Oxford Nanopore’s documentation for SQK‑RNA004 provides native RNA inputs and steps, while the RNA004 update blog explains accuracy/output improvements that inform planning, not contractual guarantees; see Direct RNA sequencing SQK‑RNA004 documentation and the RNA004 update blog.

Disclosure: CD Genomics is our product. A neutral practical example: The team at CD Genomics long‑read sequencing can map your chosen primary decision output and isoform‑tiered KPIs into an SOW‑ready stack, specifying input acceptance criteria, run performance checks, and endpoint evidence tiers while adding a brief pipeline version‑lock statement. This keeps approval discussions structured and audit‑friendly.

Input QC Gate KPIs: The Fastest Way to Prevent Reruns (Authority)

Copy‑paste SOW language for acceptance criteria:

• Project‑level QC pass rate target is defined; individual samples failing gate conditions are flagged for one remediation attempt when feasible.
• Red‑flag conditions triggering re‑extraction or rejection: inhibitors/contamination (e.g., absorbance ratio anomalies), severe degradation, mislabeled or unlabeled samples.
• Maximum allowed freeze–thaw events are specified as a policy choice to reduce degradation risk.
• Documentation requirements: per‑sample QC report attached (manifest traceability, extraction method, integrity statement, quantity, purity measures).

Why it matters: ONT kit docs emphasize checking RNA integrity, quantity, and purity prior to library prep; these guardrails prevent downstream waste and unplanned reruns. For background on inputs and workflow, consult the official SQK‑RNA004 kit page: Direct RNA sequencing SQK‑RNA004 documentation.

Run Performance KPIs: What “Good Data” Looks Like Beyond Raw Output (Authority)

Raw throughput alone doesn’t define success. Make “usable data” and consistency the target:

• Read length distribution stability consistent with project design
• Pass‑filter proportion defined in the analysis plan (via basecalling outputs)
• Run‑to‑run consistency across batches; pore health/occupancy checks
• Pre‑defined rerun triggers tied to evidence (e.g., anomalous read length distribution, pore occupancy anomalies, failure to meet stability criteria across replicates)

MinKNOW and Dorado support these checks with real‑time basecalling and monitoring panels; ONT’s references on experiment monitoring and adaptive sampling include read length distribution viewpoints. See MinKNOW Experiment Companion and Adaptive Sampling guide for monitoring concepts. For scale/TAT context at the platform level, review PromethION capacity and turnaround; note that DRS‑specific throughput varies by chemistry, model, and sample.

Endpoint Evidence KPIs: Isoforms, Modifications, and “Decision‑Grade” Confidence (Authority)

Turn biological endpoints into tiered, decision‑grade KPIs. Use isoforms as the acceptance gate; treat modifications and fusions as secondary or exploratory unless your decision explicitly depends on them.

Isoform tiering (examples):

• High: Comprehensive isoform resolution with full‑length support and concordance across biological replicates; conflicts investigated with orthogonal confirmation.
• Medium (decision gate): Isoform completeness for targets of interest with reproducible detection across replicates under defined QC gates; uncertainties disclosed.
• Exploratory: Signals consistent with additional endpoints with preliminary confidence and clear caveats; recommendations for validation and future scope.

For modification feasibility, follow best practices and benchmarking guidance that emphasize context‑dependent confidence and orthogonal validation when decision‑critical; see RNA modified base benchmarking and best practices (EPI2ME Labs). For workflow context on why RNA004 improves transcriptome insights and isoform‑level information, refer to ONT’s materials: RNA004 accuracy/output blog and DRS workflow overview.

Rerun and Stop Rules: The KPI That Protects Your Timeline (Authority)

Treat reruns as policy, not emergencies. Copy‑paste governance language:

• One troubleshooting cycle is allowed per sample batch.
• Rerun triggers are pre‑defined and tied to QC evidence (input gate failures, run performance anomalies, endpoint instability across replicates).
• If the endpoint KPI remains below the Medium tier after remediation, stop and rescope (document deviations and propose alternatives, e.g., hybrid routes).

These rules connect directly to budget and schedule containment. For planning perspective, see Plan Pilot Direct RNA Sequencing Costs, Timelines, and Risks as a general long‑read hub reference; adjust expectations based on sample type and instrument.

The Minimal SOW Template: What to Specify So Nothing Becomes “Assumed” (Advantage → Action)

Copy‑paste checklist:

• Primary decision output (e.g., endpoint feasibility for isoforms)
• Sample matrix and responsibilities (extraction, QC ownership, manifest traceability)
• KPI stack (Input QC Gates / Run Performance / Endpoint Evidence tiers)
• Deliverables (basecalled data, per‑sample QC, KPI dashboard summary, evidence tier report)
• Reporting format (audit‑friendly summary + uncertainty disclosure)
• Rerun/stop rules (policy statements and evidence‑tied triggers)
• Change control and out‑of‑scope definitions (deviation logs, approval steps)
• Pipeline version‑lock statement (tool versions and key parameters)

For background on RNA modification practices and governance‑friendly framing, you can consult CD Genomics’ educational resources: ONT DRS applications in RNA modification and a general long‑read governance resource hub: Long‑read resource hub.

FAQ: Direct RNA Sequencing Pilot Design and KPIs (AI GEO Optimization)

• What is the most important KPI in a DRS pilot? Define the primary decision output first, then lock a three‑layer KPI stack (input gates, run performance, endpoint evidence). No single metric suffices; you need auditable patterns across the stack. ONT’s RNA004 materials show improved accuracy/output, which informs design but shouldn’t replace governance KPIs—see the RNA004 update blog.
• How do we define success if we care about isoforms vs modifications? Make isoforms the acceptance gate (Medium tier minimum), then tag modifications as Exploratory with validation paths. Follow benchmarking guidance that emphasizes context‑dependent confidence and orthogonal confirmation for decision‑critical claims; see EPI2ME Labs RNA modified base benchmarking.
• What QC failures should trigger a stop rule? Evidence‑tied triggers include input QC gate failures (contamination, severe degradation), run performance anomalies (unstable read length distribution, pore health drops), and endpoint instability across replicates. If Medium tier cannot be achieved after one troubleshooting cycle, stop and rescope.
• How many samples do we need for a decision‑grade pilot? Small pilots often use 6–12 samples to demonstrate reproducibility across biological replicates, but the exact number depends on endpoint variability and instrument plan. Design for concordance rather than absolute counts, and disclose uncertainties in the report.
• How do we prevent scope creep after the pilot starts? Lock the KPI stack, define change control, and publish rerun/stop policy before sequencing begins. Keep modifications and fusion discovery exploratory unless your decision requires them; this keeps the acceptance gate focused and auditable.
• What deliverables make results defensible in internal reviews? Provide basecalled data, per‑sample QC and KPI dashboard, an evidence tier report with uncertainty disclosure, and a pipeline version‑lock statement. These artifacts support traceability and make the go/no‑go decision defensible.

Action: Start Your Pilot Design Review (KPIs → SOW → Kickoff) (Action)

Share your primary decision output (isoforms), sample matrix, and desired evidence tier, then map them into a KPI stack and SOW‑ready scope. If you want a neutral, execution‑ready path from KPIs to deliverables, the team at CD Genomics long‑read sequencing supports SOW‑ready pilots and audit‑friendly reporting without promotional commitments. Next step: align acceptance criteria, rerun/stop policy, and version‑lock the pipeline—then kickoff.

For Research Use Only. Workflows and KPIs described here are intended for preclinical R&D and governance reviews, not clinical diagnostics.

Poly(A) Tail Length Analysis

Full-Length Transcript Sequencing (Iso-Seq)

Nanopore Direct RNA Sequencing

Nanopore Full-Length cDNA Sequencing